心肌纤维化的分子影像学评价  

Molecular imaging in myocardial fibrosis

作　　者：郭应坤[1] 李真林[2] 郜发宝[2] 

机构地区：[1]四川大学华西第二医院放射科,成都610041 [2]四川大学华西医院放射科

出　　处：《中华核医学与分子影像杂志》2013年第5期398-400,共3页Chinese Journal of Nuclear Medicine and Molecular Imaging

基　　金：国家自然科学基金（81271625,30870687,81071204）;四川省科技支撑计划（2010SZ0173,2011SZ0108）;四川省卫生厅科研课题（100381）;成都市科技计划项目（11DXYB111SF）

摘　　要：随着生命科学的发展和医疗技术的进步，对心肌纤维化的干预甚至逆转已成为心脏病防治的新靶标。目前，心肌纤维化的检测临床常用心肌活组织检查和血清代谢物检测，但限制较多，不能完全满足临床需求。分子影像学技术可实现活体、无创、量化和靶向特异性评价心肌纤维化的有无、程度及转归，以便早期进行临床评估和干预。现阶段可用于心肌纤维化评价的分子影像技术主要包括SPECT、PET及MRI，不久的将来有望出现相应的分子影像探针用于心肌纤维化的超声靶向评价。With the development of life science and medical technology, myocardial fibrosis is being increasingly recognized as a new therapeutic target for heart diseases. However, traditional methods for detection of myocardial fibrosis, such as myocardial biopsy and laboratory assay of serum metabolites or en- zymes, are not satisfactory in meeting the clinical demands because of their intrinsic limitations. Molecular imaging may non-invasively and quantitatively evaluate the presence/absence, degree and turnover of inyo- cardial fibrosis in vivo with good specificity, thus being useful for clinical assessment and intervention. Cur- rently, the commonly used molecular imaging modalities for evaluation of myocardial fibrosis include SPECT, PET and MRI. It is hopeful that the molecular probe for targeted ultrasound technology may also be developed in the near future. This review highlights the current status and future trends of molecular imaging in myocardial fibrosis.

关 键 词：心肌疾病 纤维变性 分子显像 

分 类 号：R542.2[医药卫生—心血管疾病]